CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER

Autor:	I. S. Bulavina, S. Y. Krasilnikova
Jazyk:	ruština
Rok vydání:	2015
Předmět:	metastatic colorectal cancer chemotherapy bevacizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Тазовая хирургия и онкология, Vol 0, Iss 1, Pp 27-30 (2015)
Druh dokumentu:	article
ISSN:	2686-9594 2220-3478
DOI:	10.17650/2220-3478-2012-0-1-27-30
Popis:	Bevacizumab in combination with standard chemotherapy (CT) in 1st line metastatic colorectal cancer (mCRC) settings prolongs median overall survival to 20,3 months. Data of observational cohort programs suggests that bevacizumab therapy beyond disease progression, in combination with several CT regimens prolongs median overall survival till 31,8 month. Authors presents their own experience of prolonged bevacizumab therapy in mCRC patient.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/f6074f97e98f4da7b9a476c70a782890 Zobrazit plný text záznamu View record in DOAJ